Health ❯Healthcare ❯Diabetes ❯Type 2 Diabetes

GLP-1 Receptor Agonists

Medical Research Chronic Diseases Clinical Research Preventive Medicine Side Effects Market Trends Market Competition Type 2 Diabetes Diabetes Pharmaceuticals

Eli Lilly’s Oral GLP-1 Pill Matches Injectables in Weight and Blood Sugar Control

Phase 3 results show nearly 8% weight loss with tolerable side effects, setting the stage for a late-2025 obesity drug application

Tirzepatide Outperforms Semaglutide in Weight-Loss Trial

Eli Lilly's Oral GLP-1 Pill Demonstrates Success in Phase 3 Trials